Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
J Transl Med
; 8: 67, 2010 Jul 14.
Article
en En
| MEDLINE
| ID: mdl-20630094
ABSTRACT
Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Cutáneas
/
Sulfonamidas
/
Proteínas Proto-Oncogénicas B-raf
/
Indoles
/
Melanoma
/
Mutación
Tipo de estudio:
Incidence_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
J Transl Med
Año:
2010
Tipo del documento:
Article
País de afiliación:
Estados Unidos